BriaCell Therapeutics Corp.

In a Phase 2 study of 54 heavily pretreated MBC patients, the Bria-IMT™ regimen produced a median overall survival of 13.4 months – 2X those in similar studies. If you or someone you know has MBC, please learn more about BriaCell’s Phase 3 study of the Bria-IMT™ regimen. https://lnkd.in/em9Zcsra #breastcancer #MBC #clinicaltrial #newcancertreatments #innovativecancertreatments #innovativecancertherapies #clinicalstudy #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs #patientrecruitment #clinicaltrial

BriaCell’s lead candidate Bria-IMT™ is currently in a pivotal Phase 3 study for #metastaticbreastcancer. For more information, please visit: https://bit.ly/4d8P2Sf #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

In a clinical study of 54 patients, Bria-IMT™ regimen used in combination with an immune check point inhibitor was associated with longer than expected progression free survival and other clinical benefits in #metastaticbreastcancer patients. The treatment was well-tolerated. If you or someone you know has been diagnosed with metastatic breast cancer, please direct them to the following: https://lnkd.in/e79ajb2X #breastcancer #clinicaltrial #newcancertreatments #innovativecancertreatments #innovativecancertherapies #clinicalstudy #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs #patientrecruitment #clicaltrial

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ monotherapy. Learn more: https://bit.ly/40HubAz #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

BriaCell is actively recruiting patients for our pivotal Phase 3 study in #metastaticbreastcancer. https://lnkd.in/e79ajb2X In a clinical study of 54 patients, Bria-IMT™ regimen used in combination with an immune check point inhibitor was associated with longer than expected progression free survival and other clinical benefits in metastatic breast cancer patients. The treatment was well-tolerated. #breastcancer #clinicaltrial #newcancertreatments #innovativecancertreatments #innovativecancertherapies #clinicalstudy #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs #patientrecruitment #clicaltrial #MBC

BriaCell’s President and CEO, Dr. William V. Williams, stated that “This data supports our hypothesis of personalized #immunotherapy with Bria-OTS™, potentially leading to new and effective treatment of #metastaticbreastcancer." Learn more: https://bit.ly/40HubAz #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments

BriaCell’s Chief Medical Officer, Dr. Giuseppe Del Priore, stated that "The resolution of metastatic lung disease in this #breastcancer patient highlights the clinical effectiveness of Bria-OTS™, and its therapeutic potential in #MBC." https://bit.ly/40HubAz #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments

Dr. Neal Chawla, Associate Director of Clinical Research at the Sarcoma Oncology Center, and Principal Investigator for the Bria-OTS™ study, comments on the resolution of lung metastasis reported in the first patient treated with Bria-OTS™. https://bit.ly/40HubAz #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ monotherapy. Learn more: https://bit.ly/40HubAz #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

BriaCell (Nasdaq: BCTX, BCTXW) (TSX: BCT) announced an unprecedented clinical response including resolution of lung metastases (breast cancer tumor that spread to the lung) with stable disease elsewhere. This patient is the first #metastaticbreastcancer (#MBC) patient treated with Bria-OTS™. Find details: https://bit.ly/40HubAz #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs